peg-interferon

DRUG3 trials

Sponsors

Novartis, Merck Sharp & Dohme LLC, Fondazione Melanoma Onlus

Conditions

Chronic Hepatitis CMelanoma

Phase 1

Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

WithdrawnNCT01547312

Merck Sharp & Dohme LLCChronic Hepatitis C

Start: 2012-05-31End: 2012-11-30Updated: 2015-10-14

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

CompletedNCT01959633

Fondazione Melanoma OnlusMelanoma

Start: 2014-04-03End: 2018-03-26Updated: 2022-02-24

Phase 2

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

CompletedNCT00759200

NovartisChronic Hepatitis C

Start: 2008-10-31End: 2010-12-31Target: 525Updated: 2016-11-16

Related Papers

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

Journal of Translational Medicine2021-01-066 citations

Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.

Journal of Clinical Oncology2014-05-203 citations